Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): a double-blind, randomised …
Background Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …
[PDF][PDF] Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): a double-blind …
PM Ellis, FA Shepherd, M Millward, F Perrone… - Lancet …, 2014 - ctg.queensu.ca
Background Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): A double-blind, randomised …
PM Ellis, FA Shepherd, M Millward… - The Lancet …, 2014 - cuk.elsevierpure.com
Background: Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with
preclinical and clinical evidence of activity in non-small-cell lung cancer. We designed BR …
preclinical and clinical evidence of activity in non-small-cell lung cancer. We designed BR …
[引用][C] Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): A double-blind …
PM Ellis, FA Shepherd, M Millward… - The Lancet …, 2014 - research-repository.uwa.edu.au
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell
lung cancer (NCIC CTG BR.26): A double-blind, randomised, phase 3 trial — the UWA …
lung cancer (NCIC CTG BR.26): A double-blind, randomised, phase 3 trial — the UWA …
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): a double-blind, randomised …
PM Ellis, FA Shepherd, M Millward… - The Lancet …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …
[引用][C] Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): a double-blind …
PM Ellis, FA Shepherd, M Millward, F Perrone… - The Lancet …, 2014 - cir.nii.ac.jp
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell
lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial | CiNii Research …
lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial | CiNii Research …
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): a double-blind, randomised …
PM Ellis, FA Shepherd, M Millward, F Perrone… - The Lancet …, 2014 - europepmc.org
Background Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): a double-blind, randomised …
PM Ellis, FA Shepherd, M Millward, F Perrone… - The Lancet …, 2014 - Elsevier
Background Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): A double-blind, randomised …
PM Ellis, FA Shepherd, M Millward… - The Lancet …, 2014 - yonsei.elsevierpure.com
Background: Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with
preclinical and clinical evidence of activity in non-small-cell lung cancer. We designed BR …
preclinical and clinical evidence of activity in non-small-cell lung cancer. We designed BR …
[PDF][PDF] Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): a double-blind …
PM Ellis, FA Shepherd, M Millward, F Perrone… - 2014 - academia.edu
Background Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …